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Abstract
Background: To explore the clinical characteristics and pathological features of epithelioid inflammatory
myofibroblastic sarcoma (EIMS) with emphasis on the diagnostic spectrum.
Methods: The clinical data and histological features in 5 additional cases of EIMS were retrospectively reviewed.
Immunohistochemical study and interphase fluorescence in situ hybridization (FISH) analysis were carried out.
Results: There were 2 males and 3 females with age at presentation ranging from 15 to 58 years (mean, 37 years).
All 5 tumors were intra-abdominal with 2 arising in the mesentery and 1 each in the omentum, rectum and
transverse colon. The tumor size ranged from 5 to 20 cm in maximum diameter (mean, 10.7 cm). Histologically, all 5
tumors were composed predominantly of large epithelioid cells possessing vesicular nuclei, prominent nucleoli, and
amphophilic cytoplasm. Mitotic figures were easily identified (mean, 20/10HPF). Tumor cells were arranged in
clusters or sheets embedded in a myxoid stroma containing prominent neutrophils. A minor component of spindle
cells was present in focal areas. By immunohistochemistry, all 5 cases were positive for anaplastic lymphoma kinase
(ALK) with a nuclear membrane pattern in 4 and cytoplasmic staining with perinuclear accentuation in 1. Besides
ALK, tumor cells stained variably for desmin (4/5), alpha smooth muscle actin (2/5), muscle-specific actin (1/2) and
pan-cytokeratin (1/4). FISH analysis demonstrated the presence of ALK rearrangement in all 5 cases. Of 5 patients, 3
developed local recurrence, 1 died of disease 8 months after surgery.
Conclusion: EIMS represents a highly aggressive variant of inflammatory myofibroblastic tumor characterized by
epithelioid morphology, prominent neutrophilic infiltrate, and nuclear membrane staining of ALK with ALK
rearrangement. As patients with ALK-rearrangement tumors may benefit from targeted therapy, accurate diagnosis
of EIMS is very important. Familiar with the characteristic features of EIMS will help pathologists avoid
misdiagnosing the tumor as other malignancies.
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Background
Inflammatory myofibroblastic tumor (IMT) is a distinct
mesenchymal neoplasm composed of spindled fibroblas-
tic and myofibroblastic cells in a myxoid to collagenous
stroma containing abundant lymphocytic and plasmacy-
tic inflammatory infiltrate [1]. IMT usually affects chil-
dren and adolescents, although a broad age range has
been documented. The most common anatomical loca-
tions are the abdominopelvic region, lung, mediastinum
and retroperitoneum [1]. Approximately 50 % of IMTs
aberrantly express anaplastic lymphoma kinase (ALK)
protein triggered by clonal rearrangements of ALK gene
located on chromosome 2p23 [2]. IMT is considered to
be a soft tissue tumor with an intermediate biological
behavior. However, a small percentage of cases behave
aggressively [3].
In 2011, Mariño-Enríquez et al. [4] described a novel
variant of IMT, which they nominated as epithelioid in-
flammatory myofibroblastic sarcoma (EIMS). In contrast
to the classic IMT, EIMS is characterized by an epitheli-
oid morphology accompanied with prominent neutro-
philic inflammatory infiltrate. Clinically, it also differs
from the classic IMT by a more aggressive behavior with
short disease-free survival. Recognizing EIMS as a dis-
tinct variant of IMT is very important as patients with
ALK-rearrangement EIMS may benefit from targeted
therapy. As EIMS has not been widely recognized, we
present here 5 additional cases of EIMS with a clinico-
pathological, immunohistochemical and molecular cyto-
genetic analysis.
Methods
Five cases of EIMS were retrieved from the archive
files of the Department of Pathology, Fudan University
Shanghai Cancer Center. The cases were initially diag-
nosed between 2012 and 2015 and were all consult-
ation cases. The clinical and follow-up data were
obtained from the electronic medical records, hospital
discharge summary or by telephone inquiry. All avail-
able hematoxylin-and-eosin (H&E) slides were reas-
sessed for cytomorphology, mitotic activity, composition of
inflammatory infiltrate, stromal change, and presence of
necrosis.
Immunohistochemical study was performed on paraffin-
embedded sections on Ventana Benchmark XT autostainer
(Roche). The primary antibodies used in the study in-
cluded desmin (D33, dilution 1:500; DAKO), alpha smooth
muscle actin (1A4, dilution 1:400; DAKO), muscle-specific
actin (HHF-35, dilution 1:400; DAKO), H-caldesmon (h-
CALD, dilution 1:400; DAKO), ALK (5A4, dilution 1:100;
DAKO), CD30 (Ber-H2, dilution 1:50; DAKO), vimentin
(V-9, dilution 1:200; DAKO), S100 protein (polyclonal,
dilution 1:300; DAKO), pan-cytokeratin(AE1/AE3, dilution
1:100; DAKO), epithelial membrane antigen (E29,dilution
1:150; DAKO), myogenin(MYF4, dilution 1:500; Novocas-
tra), CD117 (polyclonal, dilution 1:100; DAKO), discovered
on GIST-1 (DOG1) (SP31, dilution 1:100; DAKO),
CD34(QBEnd/10, dilution 1:50;DAKO) and Ki-67(MIB-1,
dilution 1:150; DAKO). Appropriate positive and negative
controls were run simultaneously for all antibodies tested.
Interphase fluorescence in situ hybridization analysis
was carried out on 5-μm-thick sections of formalin-
fixed, paraffin-embedded tissue in 5 cases, according to
the manufacturer’s protocol. The presence of ALK gene
rearrangement at 2p23 was tested using the LSI ALK
dual-color break-apart probe (Abbott Molecular, Vysis,
Des Plaines, IL). The fluorescence signals were analyzed
using an Olympus BX51 fluorescence microscope (Olym-





A 37-year-old woman went to the clinic of a local hospital
because of abdominal pain and hematochezia for one
week. Colonoscopy examination showed a polypoid mass
protruding into the rectum cavity, measuring approxi-
mately 5 cm in maximum diameter, with a rough and
uneven surface (Fig. 1). Then the patient underwent a par-
tial rectectomy. The lesion was considered as a myogenic
sarcoma, preferring pleomorphic leimyosarcoma by the
referring pathologists. The postoperativ adjunctive therapy
was not administrated . There was no evidence of recur-
rence or metastasis 8 months after surgery.
Fig. 1 Endoscopic appearance of EIMS. Colonoscopy examination
showed a polypoid mass protruding into the rectum cavity
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Case 2
The patient was a 55-year-old man who complained of
abdominal pain and distension lasting for two days.
Physical examination showed abdominal mass with ten-
derness. No obvious mass was found by colonoscopy.
X-ray displayed intestinal obstruction. Computed tom-
ography (CT) scan demonstrated a solid mass in the
pelvic cavity (Fig. 2). Clinically, the lesion was suspi-
cious of gastrointestinal stromal tumor (GIST). Intra-
operatively, the mass was found on the terminal ileum
nearing the ileocecal junction. Partial ileal resection
and appendectomy with intestinal anastomosis were
performed shortly after. The lesion was originally diag-
nosed as malignant mesothelioma by the referring path-
ologist. After reevaluation of the H&E slides with
application of immunohistochemistry and FISH analysis,
the diagnosis of EIMS was finally rendered. The patient
developed local recurrence 2 months after surgery. A re-
excision of the recurrent tumor with adjuvant chemother-
apy was performed. He was free of disease at 10-month
follow up.
Case 3
A 22-year-old young man presented with abdominal
mass with intermittent abdominal pain for eight days
and fever for five days. Subsequent CT scan revealed a
solid heterogeneous mass of the right abdominal cavity,
suspicious of GIST. After the admission, the patient
underwent a complete excision of the abdomen mass
and partial transverse colectomy soon. Intraoperatively,
an enormous mass measuring approximately 20 × 15 cm
was identified, with multiple small omental or mesen-
teric nodules. Pathological examination of the submitted
specimen showed that malignant tumor was suspected
as GIST. To confirm the diagnosis, the pathological
materials were sent to our department for further con-
sideration. With the adjunctive study of immunohisto-
chemistry and FISH, the lesion was re-diagnosed as
EIMS. The patient developed local recurrence 2 months
after surgery. The targeted therapy of ALK inhibitor (cri-
zotinib) was administrated later. He achieved a partial
response to the treatment. He was alive with disease at
14-month follow up.
Case 4
The patient was a 58-year-old woman who complained
of a slowly enlarging and painless mass on the abdomen
for two months. Physical examination showed an ill-
defined solid mass of the right lower abdominal wall
with no tenderness. Then she received a local resection.
Intraoperative examination revealed that the mass was
firm in consistency and infiltrated into the skeletal
muscle of the abdomen wall. Pathologically, the tumor
was considered as pleomorphic sarcoma by the referring
pathologist. After surgery, the patient was treated with
the additional chemotherapy. She developed local recur-
rence 2 months later and died of disease at 8-month
follow-up.
Case 5
A 15-year-old young woman complained of recurrent ab-
dominal pain for four months and abdominal mass for four
days. Physical examination revealed a well-defined solid
mass of the right abdomen with mild tenderness. Ultrason-
ography displayed an abdominal tumor with heterogeneous
internal echoes, measuring about 10.2 × 7.5 cm. Subse-
quently, the patient received a complete excision of the
abdomen mass and partial transverse colectomy. During
the operation, the tumor was identified on the transverse
colon and measured approximately 12 × 8 cm, with mul-
tiple enlarged omental or mesenteric lymph nodes. The
lesion was considered as fibrosarcoma with inflammatory
cell infiltrates by the referring pathologist. After surgery,
the patient did not receive the adjunctive therapy. She was
free of disease at 7-month follow up.
Pathologic features
Tumor size ranged from 5 to 20 cm in maximum diam-
eter (mean, 10.7 cm). On cut section, the tumors were
grayish-white to pink-tan in color, moderate or fleshy in
consistency, with myxoid appearance in some areas.
On low power, the tumor displayed a polypoid appear-
ance in case 1, which was mainly located on the sub-
mucosa and infiltrating the muscularis. In case 2 and 3,
the masses invaded the intestinal wall (Fig. 3a). In case
5, the tumor was located on the submucosa and muscu-
laris and invaded into the serosa. Tumor cells were pre-
dominantly composed of non-cohesive sheets or clusters
of round to epithelioid cells embedded in a loose or
Fig. 2 Imaging features of EIMS. Computed tomography (CT) scan
revealed an enormous heterogeneous mass in the pelvic cavity
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myxoid stroma containing abundant neutrophilic in-
flammatory infiltrates (Fig. 3b). On high power, tumor
cells possessed large vesicular nuclei with prominent
nucleoli and amphophilic cytoplasm (Fig. 3c). The mi-
totic figures were easily encountered with a mean
count of 20/10 HPF (range, 12-35/10HPF). Atypical
forms were also present. There was a minor compo-
nent of spindle cells comprising less than 10 % of the
tumor in all cases (Fig. 3d). The stroma was predomin-
antly myxoid in 4 cases, and collagenous in 1. Focal ne-
crosis was present in 3 cases. Lymphovascular invasion
was seen in case 5.
Immunohistochemical and molecular findings
Immunohistochemically, all 5 tumors were strongly
positive for ALK, with nuclear membrane pattern in 4
cases (Fig. 4a), and cytoplasmic staining with peri-
nuclear accentuation fashion in 1case (Fig. 4b). Besides
ALK, tumor cells also showed variable expression of
desmin (4/5) (Fig. 4c), smooth muscle actin (2/5),
muscle-specific actin (1/2) and AE1/AE3 (1/5). Other
markers, including CD30, h-caldesmon, myogenin, epi-
thelial membrane antigen, CD117, DOG1, CD34 and
S-100 protein, were all negative. Ki-67 index was 15 %
~ 50 % (mean, 30 %).
By FISH analysis, all 5 tumors showed ALK gene
rearrangement, as indicated by the presence of isolated
green (centromeric) and orange (telomeric) signals
flanking the ALK locus at 2p23 (Fig. 4d).
Discussion
IMT is a well-described entity with a predilection for
children and adolescents and occurs predominantly in
the upper respiratory tract, lung and abdomen. Histo-
logically, it is composed of spindled fibroblasts and
myofibroblasts with occasional “ganglion-like” cells
present in the tumor. IMT with prominent epithelioid
cytomorphology is very rare. In a study with 73 cases
of IMT, Cook et al. found 4 cases that exhibited round
cell transformation characterized by large polygonal
cells with large nuclei and prominent nucleoli, in a
loose, pale staining background [5]. In contrast to classic
IMT, these four cases displayed more aggressive behavior.
They proposed for the first time the nomenclature of
“round cell transformation” to emphasize this distinctive
feature. One of these 4 cases showed distinctive nuclear
membrane staining pattern of ALK. Subsequent studies
further demonstrated that this distinctive nuclear mem-
brane staining pattern of ALK corresponded to ALK-
RANBP2 fusions [6-8]. In 2010, Butrynski et al. reported
sustained partial response to the ALK inhibitor crizotinib
in a patient with ALK-translocated IMT with epithelioid
cytomorphology [9]. Their report indicated that this
aggressive form of IMT merited a separation from the
classic IMT. In 2011, Marino-Enriquez et al. [4] de-
scribed the clinicopathologic, immunohistochemical and
genetic features of 11 additional cases in detail and pro-
posed the designation as EIMS to highlight both the dis-
tinct morphology and malignant behavior of this aggressive
form of IMT.
Fig. 3 Histological features of EIMS. a A mesenteric tumor infiltrated the adjacent small bowel wall (40 × original magnification). b The tumor was
composed predominantly of sheets of round-to-epithelioid cells with a prominent inflammatory infiltrate (200 × original magnification).c The epithelioid
tumor cells showed vesicular nuclei, large and prominent nucleoli, and amphophilic-to-basophilic cytoplasm (400 × original magnification).d A minor
spindle cell component was present in all cases (100 × original magnification)
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As EIMS has not been widely recognized, the inci-
dence remains underestimated. To the best of our know-
ledge, only about 20 cases have been documented in the
English literature [4–12]. In this study, we describe a
small series of 5 additional cases, increasing the number
of reported EIMS to 25. The clinical features of these
EIMSs are summarized in Table 1. Of these 25 cases,
18(72 %) patients were adults, and the other 7 patients
were children and adolescents. Overall, the median and
average ages of patients with EIMS were 34 and 30.7 years,
respectively (range, 7 months-63 years). There was a
prominent male predilection with a male to female ratio of
5.3:1. With regard to the location distribution, 21(84 %) tu-
mors occurred in the intra-abdominal sites, including the
mesentery, omentum, peritoneum, abdominal cavity and
retroperitoneum, 3 in the organs (1 each in liver, rectum
and transverse colon), and another 1 in the pleural cavity.
The tumor size (unavailable in 5 cases) ranged from 5 to
26 cm in maximum diameter, with an average size of
13.2 cm.10 tumors were multifocal at the time of diagno-
sis, consisting of a large dominant mass and multiple small
omental, mesenteric or peritoneal nodules. Clinically, pa-
tients usually manifested with abdominal pain or masses,
sometimes with ascites.
EIMS has distinctive morphological features. The
tumor is typically characterized by loosely arrayed,
round or epithelioid neoplastic cells with vesicular nu-
clei, prominent large nucleoli and amphophilic to eo-
sinophilic cytoplasm distributed in a widespread myxoid
stroma. The striking feature of EIMS is the presence of
obvious inflammatory infiltrates frequently composed of
neutrophils. All tumors almost contained a small amount
of spindle cell component. Immunohistochemically, EIMS
demonstrated a unique nuclear membrane staining pat-
tern of ALK, which was observed in 80 % (20/25) of cases
(Table 2). However, several cases (20 %, 5/25) showed
ALK perinuclear or cytoplasmic staining pattern. Another
diagnostic immunophenotype is diffuse and strong expres-
sion of desmin in almost all cases (86.4 %, 19/22). In
addition, the tumor displayed variable expression of CD30
(61.1 %, 11/18), alpha smooth muscle actin (47.4 %, 9/19)
and cytokeratin (15.8 %, 3/19).
Approximately 50 % of IMTs aberrantly express ALK
protein triggered by clonal rearrangements of ALK gene
located on chromosome 2p23 [3]. A variety of ALK part-
ner genes have been subsequently identified in IMT owing
to diverse chromosomal rearrangements, including TPM3
at 1p23, TPM4 at 19p13, CLTC at 17q23, CARS at 11p15,
ATIC at 2q35, SEC31L1 at 4q21, PPFIBP1 at 12p11 and
ran-binding protein 2 (RANBP2) at 2q13 [13–17]. Differ-
ent fusion partners may result in distinct ALK staining
pattern when detected by ALK antibody. IMT with TPM3,
TPM4, CARS, ATIC, and SEC31L1 fusion often shows
diffuse cytoplasmic staining of ALK [5, 6], whereas with
CLTC fusion, displays granular cytoplasmic staining [14].
By comparison, EIMS harbors a specific RANBP2-ALK
fusion genes resulting from t (2;2) (2q12;2p23). All 21
cases tested by FISH so far showed positive signal of ALK
Fig. 4 Immunohistochemical and genetic features of EIMS. a Immunohistochemistry for ALK showed a nuclear membrane staining pattern
(400 × original magnification). b Case 3 showed ALK cytoplasmic staining with perinuclear accentuation (200 × original magnification). c Diffuse
and strong positivity for desmin (200 × original magnification). d Fluorescence in situ hybridization (FISH) showed split apart of the red and green
signals, confirming the presence of ALK rearrangement (1000 × original magnification)
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Table 1 Clinical features of 25 cases of epithelioid inflammatory myofibroblastic sarcoma
Case Age/Sex Site Size (cm) Multifocal Treatment Recurrence Metastasis Follow up Source
1 7y/M Abdominal cavity NA No SE, CT Yes (5w, 5 m) No NED(5 m) Ma et al. [7]
2 7 m/M Mesentery and omentum 11 Yes SE Yes (8 m) No AWD(8 m)
3 2y/M Retroperitoneal and abdominal cavity 10 No SE No No NED(36 m) Patel et al. [6]
4 34y/M Liver 8 No SE Yes (5 m) No DOD(5.5 m) Chen et al. [8]
5 44y/M Omentum NA Yes SE, CT, ALKi Yes (5 m) Liver (12 m) AWD(39 m) Butrynski et al. [9]
6 41y/M Omentum 26 Yes ST, CT, ALKi Yes (12 m) Liver(12 m) NED(40 m) Marino-Enriquez
et al. [4]
7 59y/M Mesentery of small bowel 15 Yes SE, CT Yes No DOD (12 m)
8 6y/M Omentum 10.5 No SE, CT Yes No AWD(3 m)
9 28y/M Mesentery of small bowel NA Yes NA NA NA NA
10 63y/M Mesentery of small bowel 25 No SE, CT Yes No DOD(3 m)
11 42y/M Intra-abdominal NA No SE, CT Yes No AWD(13 m)
12 7 m/M Peritoneum 10 No SE, CT, RT Yes No DOD(36 m)
13 40y/M Peritoneum 8 No SE, CT, RT Yes Lung, liver, and lymph node
14 31y/M Mesentery of small bowel 17.5 Yes SE, CT Yes No DOD(11 m)
15 6y/M Omentum and mesentery 14 Yes SE NA NA NA
16 39y/M Mesentery of small bowel 15 Yes SE NA NA NA
17 57y/M Pleura or chest wall NA NA ALKi NA NA NA Kozu et al. [10]
18 19y/F Mesentery of small bowel 19 No SE Yes(9w) No DOD(12w) Li et al. [11]
19 39y/M Mesentery of colon 15 No SE, CT Yes(4 m) No AWD(12 m)
20 22y/M Mesentery of small bowel 6 Yes SE, CT, ALKi Yes(3 m, 4 m) No AWD(14 m) Kimbara et al. [12]
21 37/F Rectum 5 No SE No(8 m) No NED(8 m) Current cases
22 55/M Mesentery of ileum 11 No SE, CT Yes(2 m) No NED(10 m)
23 22/M Mesentery of colon 20 Yes SE, ALKi Yes(2 m) No AWD(14 m)
24 58/F Omentum 5.5 No SE, CT Yes(2 m) No DOD(8 m)
25 15/F Transverse colon 12 No SE No(7 m) No NED(7 m)











Table 2 Immunohistochemical and genetic features of 25 cases of epithelioid inflammatory myofibroblastic sarcoma
Case Immunohistochemical features ALK
desmin SMA H-caldesmon CD30 CK EMA S-100 myogenin IHC FISH RT-PCR
1 NA NA NA NA NA NA NA NA NM+ + RANBP2-ALK
2 NA NA NA NA NA NA NA NA NM+ + RANBP2-ALK
3 + + - NA + NA - NA PN+ + RANBP2-ALK
4 - - NA - - NA - NA NM+ NA RANBP2-ALK
5 + - NA + - - - - NM+ + RANBP2-ALK
6 + - - + - - - - NM+ + RANBP2-ALK
7 + + NA NA - NA - - NM+ + NA
8 + - NA NA - NA - - NM+ + NA
9 + + NA + - - - NA NM+ NA NA
10 + - - + - - - - PN+ + NA
11 + NA NA NA NA NA NA NA NM+ NA NA
12 + NA - + NA NA NA - PN+ + NA
13 - + - + - - - - NM+ + NA
14 + - - + - NA - - NM+ + NA
15 + NA - + NA NA NA NA NM+ + RANBP2-ALK
16 + + - + - NA - - NM+ + RANBP2-ALK
17 + - NA - + NA - NA PN+ + NA
18 + + - + - - - - NM+ + NA
19 + + - + - - - - NM+ + RANBP2-ALK
20 NA NA NA NA NA NA NA NA NM+ NA RANBP2-ALK
21 + - - - - NA - - NM+ + NA
22 + - NA - - - - - NM+ + NA
23 + - - - - - - - PN+ + NA
24 + Focal + - - Focal + NA - - NM+ + NA
25 - + NA - - - - - NM+ + NA
Total 86 % (19/22) 47 % (9/19) 0 % (0/13) 61 % (11/18) 16 % (3/19) 0 % (0/10) 0 % (0/19) 0 % (0/16) 100 % (25/25) 100 % (21/21) 100 % (10/10)
CK cytokeratin, EMA epithelial membrane antigen, FISH fluroscence in situ hybridization, IHC immunohistochemistry, NA not avaiable, NM nuclear membrane staining, PN cytoplasmic staining with perinuclear











translocation. Of note, all 10 cases in which the cDNA fu-
sions were examined by reverse transcription-polymerase
chain reaction (RT-PCR) constantly presented identical fu-
sion points between exon 18 of RANPB2 and exon 20 of
ALK (Table 2). The fusion partner of RANBP2 encodes a
nuclear pore protein, attributing to the nuclear membrane
or perinuclear staining pattern in EIMS. 9 cases except for
one confirmed by RT-PCR in previous studies reported to
contain RANBP2-ALK fusion showed this distinct stain-
ing pattern [4-9, 11, 12]. The biology function of the
RANBP2-ALK fusion protein remains largely unknown.
Several studies discovered that the chimeric RANPB2-
ALK gene could promote cell growth and proliferation in-
dependent of cytokine in vitro [18, 19]. Furthermore,
nearly all reported cases containing RANBP2-ALK fusion
gene pursued an aggressive behavior [4, 5, 7, 9, 11, 12].
Accordingly, we infer that RANPB2-ALK fusion gene
might be a potential molecular mechanism for the rapid
growth and recurrence of EIMS. However, further investi-
gations are still needed to establish the relationship this
fusion gene with aggressive clinical course of EIMS.
EIMS can be diagnosed in combination with morpho-
logic features and an appropriate immunohistochemical
panel. Nonetheless, it is possibly risky to diagnose EIMS
rely solely on the histology or ALK expression, because
not all IMTs with epithelioid/round cell morphology
carry the genetic alteration of EIMS [5], as well as ALK
cytoplasmic staining could be encountered in a few mes-
enchymal tumors, such as rhabdomyosarcoma, malig-
nant peripheral nerve sheath tumor, leiomyosarcoma,
lipogenic tumors, and Ewing sarcoma/ peripheral primi-
tive neuroectodermal tumor [20, 21]. Therefore, for those
cases with atypical morphology or immunoprofile, we rec-
ommend further genetic detection of ALK rearrangement
by FISH or RT-PCR to confirm the diagnosis of EIMS.
A variety of tumors should be included into the differen-
tial diagnoses of EIMS. Anaplastic large cell lymphoma
(ALCL) is the most likely to be confused with EIMS, be-
cause both tumors have an overlapping immunophenotype
and cytogenetic feature, including reactivity for CD30,
ALK and SMA, and the presence of ALK rearrangement
[22]. Detection of ALK translocation by FISH would not be
helpful in the distinction of both tumors. However, strong
expression of desmin and nuclear membrane ALK staining
are not observed in ALCL. Moreover, ALCL is absent of
RANBP2-ALK fusion gene in EIMS, which can be detected
by RT-PCR. In addition, epithelioid leiomyosarcoma also
needs to be differentiated from EIMS, but the former usu-
ally contains at least focal areas of typical spindle cell lei-
myosarcoma and is lacking of ALK nuclear membrane
expression. Other tumors with round or epithelioid morph-
ology may also be discriminated from EIMS, such as solid
variant of alveolar rhabdomyosarcoma, epithelioid gastro-
intestinal stromal tumor, epithelioid malignant peripheral
nerve sheath tumor, myxoid/round cell liposarcoma, myxo-
fibrosarcoma, poorly differentiated carcinoma, and melan-
oma. However, these entities can be easily distinguished by
their lack of nuclear membrane ALK staining and their
respective morphology and immunophenotypes.
With respect to the biologic behavior of EIMS, 8 of 21
patients with follow-up information died of the disease (6
within 1 year of diagnosis, 2 within 3 years of diagnosis), 7
was alive with disease, and the other 6 remained well with
no evidence of disease [4-9, 11, 12]. The median time of
overall survival was 11 months (mean, 15.4 months). Fur-
thermore, 18 patients experienced local recurrence, and 3
developed distant metastases (2 to liver, 1 to lung, liver
and lymph node) [4, 5, 7, 9, 11, 12]; its local recurrence
rate (86 %, 18/21) and distant metastasis rate (14 %, 3/21)
are both markedly higher than those of the conventional
IMT. The data indicate that EIMS pursues a more aggres-
sive biologic behavior than the usual IMT. Up to present,
the clinicopathologic factors related to prognosis of EIMS
is still unknown. Several studies suggested that its abdomi-
nopelvic origination, bigger tumor size, epithelioid morph-
ology and RANBP2-ALK are possibly related to its
aggressive course [4, 5, 7, 9, 11, 12, 23].
The optimal therapy of EIMS has not been well
established. A surgical resection remains to be consid-
ered as the mainstay of treatment. In view of postoper-
ative adjuvant therapy, available experiences are very
limited. Most of reported cases are administrated by
postoperative chemotherapy or radiotherapy, but it
seems to have no obvious effects in the control of rapid
recurrence [4, 7, 9, 11, 12]. Recently, ALK inhibitor,
crizotinib, has been applied in the treatment of EIMS
with certain effectiveness [4, 9, 10, 12, 24]. Thus, crizo-
tinib might serve as a provisional adjuvant in the ther-
apy of EIMS. In our own series, case 3 was treated with
ALK inhibitor (crizotinib) after the recurrence. Follow-
up CT scan showed that the residual tumor partially
shrinked in size. The patient felt well after four courses
of treatment.
Conclusion
In summary, EIMS is a highly aggressive IMT variant
characterized by epithelioid cytomorphology, often neu-
trophilic inflammatory infiltrate, loose or myxoid stroma
and distinctive nuclear membrane or perinuclear ALK
staining. It has a striking male predominance and mostly
arises in the intra-abdominal locations. Familiarity with
histologic features of this special tumor type with appli-
cation of an appropriate immunohistochemical panel
can arrive to a correct diagnosis. Detection of ALK re-
arrangement by FISH or RT-PCR will further confirm
the diagnosis of EIMS and provide a reliable reference
for ALK-targeted therapy.
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